Premium
Propranolol‐resistant infantile haemangiomas
Author(s) -
Caussé S.,
Aubert H.,
SaintJean M.,
Puzenat E.,
Bursztejn A.C.,
Eschard C.,
Mahé E.,
Maruani A.,
MazereeuwHautier J.,
Dreyfus I.,
Miquel J.,
Chiaverini C.,
Boccara O.,
HadjRabia S.,
Stalder J.F.,
Barbarot S.
Publication year - 2013
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1111/bjd.12417
Subject(s) - propranolol , medicine , pediatrics , dermatology
Summary Backround Propranolol is now widely used to treat severe infantile haemangiomas ( IH s). Very few cases of propranolol‐resistant IH ( PRIH ) are mentioned in the literature. Objectives To describe the characteristics of PRIH s. Methods A national, multicentre, retrospective, observational study was conducted from February 2011 to December 2011. All patients with PRIH evaluated by the members of the Groupe de Recherche Clinique en Dermatologie Pédiatrique from 1 January 2007 to 1 December 2011 were eligible. Results Among 1130 patients treated with propranolol for infantile haemangioma, 10 (0·9%) had PRIH s. Haemangioma propranolol resistance was observed at all ages during early childhood and at any proliferation stage. Conclusions PRIH is a rare phenomenon that raises questions and merits further investigation.